CCEL earnings analysis
What we found in CCEL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Cryo-Cell International, Inc. reported Q2 2026 revenues of $7.78 million, down 2% from $7.93 million in Q2 2025, with diluted EPS of $0.07. Although revenue slightly declined year-over-year due to a decrease in new cord blood specimens processed, cost of sales saw a notable reduction, improving margins. Management emphasizes ongoing efforts to enhance operational efficiency amidst challenges in compliance and market competition.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Decline at 2%
- Q2 2026 revenue was $7.78M vs $7.93M in Q2 2025.
- EPS Improvement
- Diluted EPS of $0.07 for Q2 2026 up from $0.04 in Q1 2025.
- Cost Reduction
- Cost of sales decreased by 10% to $1.68M from $1.86M in Q2 2025.
- Increased Storage Fees
- Recurring annual storage fees increased by 3% despite fewer new accounts.
- Strong Cash Flow Performance
- Net cash provided by operations was $2.50M for the six months ending May 31, 2026.
- Operational Efficiency Sustained
- Cost of sales reduction led to an improvement in gross margin.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Compliance with NYSE Standards
- Received notice of non-compliance, requiring a compliance plan by September 2027.
- Duke License Disputes
- Ongoing arbitration against Duke University may affect future capital needs and operational plans.
- Market Competition Risks
- Increased competition from public cord blood banks impacting market share and pricing.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.07
What they said about what is next.
Management anticipates a focus on increasing revenue through improved operational efficiency but has not set explicit targets.
The filing reads about the same as the one before it.
What came before.
- 10-Q · April 14, 2026
- Q1 revenue declined to $7.683M (down $285,763, -3.6% y/y) while gross margin improved to 78.5% from 75.1%. Operating income fell to $765,134 (down $290,877, -27.5% y/y) and EPS declined to $0.01 from $0.03. Operating…
- 10-K · February 27, 2026
- Cryo-Cell (CCEL) remains a specialized cord blood and tissue storage operator with three reportable segments (family storage, PrepaCyte® CB manufacture, and public cord blood storage) and a large asset base of stored…
- 10-Q · April 14, 2025
- Cryo-Cell reported slight revenue growth to $7,968,880 for the three months ended February 28, 2025 (up $116,645 vs. $7,852,235). Operating income improved to $1,056,011 (operating margin ~13.3%), and operating cash…
- 10-Q · July 15, 2024
- Q2 results show modest top-line growth to $8.04M and stronger profitability: operating income rose to $1.39M and net income to $655,790 (EPS $0.08). Liquidity was supported by a $3.2M line draw, but the balance sheet…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CCEL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever